Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Seattle biotech startup Rhizome Research has emerged from stealth with technology for creating small-molecule drug candidates ...

Google DeepMind has expanded its AlphaFold AI system to not only predict the structure of proteins, but also to model how proteins interact with other cell structures, including DNA, RNA, and small ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

Isomorphic Labs, the London-based, drug discovery–focused spinout of Google AI R&D division DeepMind, today announced that it’s entered into strategic partnerships with two pharmaceutical giants, Eli ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...

The Beijing-based AI-for-Science firm said the Series C round would fund hiring and R&D, as interest grows in using AI to ...